What to Know About the EYLEA Biosimilars

What to Know About the FDA-Approved EYLEA (aflibercept) Biosimilars The Food and Drug Administration(FDA) approved two interchangeable EYLEA biosimilars on Monday, May 20th. This encourages the potential for greater patient accessibility to drugs for the treatment of wet age-related macular degeneration, macular edema, diabetic retinopathy, and other ophthalmic conditions. However, with the approval of these biosimilars comes new challenges for providers. These can include staying current with medication coding, pricing information, and knowledge of the new biosimilar treatments so you can administer high-quality care, efficiently conduct benefits investigations, and submit insurance claims. Today, we’ll discuss EYLEA and the new biosimilars YESAFILI and OPUVIZ, including how they impact your practice and

Read More »